Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL333812 | 0.93 | ALOX5 (0.43) | THRBSMN1; SMN2TP53MAPTALOX5 | |
| SCHEMBL4223256 | 0.92 | PTGES (0.46) | THRBSMN1; SMN2TP53MAPTPOLB | |
| SCHEMBL333728 | 0.91 | ALOX5 (0.45) | THRBSMN1; SMN2TP53MAPTALOX5 | |
| SCHEMBL334349 | 0.90 | PPARG (0.44) | AKR1C3AKR1C2PPARGPPARAMEN1 | |
| SCHEMBL334190 | 0.90 | SCN9A (0.45) | THRBSMN1; SMN2TP53MAPTPOLB | |
| SCHEMBL333779 | 0.86 | PPARG (0.47) | THRBSMN1; SMN2TP53MAPTPOLB | |
| SCHEMBL4223259 | 0.86 | SMN1; SMN2 (0.38) | THRBSMN1; SMN2TP53MAPTALOX5 | |
| SCHEMBL334099 | 0.85 | ALOX5 (0.45) | THRBSMN1; SMN2TP53MAPTALOX5 | |
| SCHEMBL333940 | 0.85 | PTGES (0.44) | THRBSMN1; SMN2TP53MAPTPOLB | |
| SCHEMBL334124 | 0.85 | ALOX5 (0.43) | THRBSMN1; SMN2TP53MAPTALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097623-B2 | 1-Aryl-or heteroaryl-3-aryl-or heteroarylindole-2-carboxylic acids or esters: e.g., 5-(4-tert-Butylphenyl)-1,3-bis(4-isopropoxyphenyl)-indole-2-carboxylic acid; inhibition of the activity of microsomal prostaglandin E synthase-1, leukotriene C4 and/or 5-lipoxygenase-activating protein; analgesics | BIOLIPOX AB (SE) | 2012-01-17 | — | — | US | disclosed |
| EP-1841735-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2011-03-09 | — | — | EP | disclosed |
| US-20090076004-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090042949-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-02-12 | — | — | US | disclosed |
| EP-1841735-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006077366-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042949-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, AREG | THRB 433/4885SMN1; SMN2 3779/4885TP53 716/4885 |
| US-20090076004-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, AREG | THRB 575/4885SMN1; SMN2 3963/4885TP53 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.